Clinical TrialJul 20, 2026, 05:01 PM
Telix Doses First Patient in Phase 3 LUTEON1 Trial for Kidney Cancer
AI Summary
Telix Pharmaceuticals Ltd announced that the first patient has been dosed in its Phase 3 LUTEON1 clinical trial. The study evaluates TLX250-Tx (lutetium-177 girentuximab tetraxetan) as a treatment for relapsed or recurrent clear cell renal cell carcinoma (ccRCC). This marks the first Phase 3 study of a CAIX-targeted radiopharmaceutical therapy in ccRCC, representing a significant step in developing new treatment options for this aggressive cancer.
Key Highlights
- First patient dosed in Phase 3 LUTEON1 trial evaluating TLX250-Tx.
- TLX250-Tx is a CAIX-targeted radiopharmaceutical therapy for relapsed or recurrent ccRCC.
- LUTEON is the first Phase 3 study of its kind for clear cell renal cell carcinoma (ccRCC).
- TLX250-Tx targets CAIX, which is expressed in over 95% of ccRCC.
- The study uses Telix's investigational PET imaging agent, TLX250-Px (Zircaix), to identify eligible patients.
Price Impact
More from TLX